Lyell Quiet as Bigger CAR-T Question Lingers for Investors
Lyell Immunopharma stock posted a late rebound to close out the short week, gaining almost 3% to finish at $17.33 on Friday. Shares moved in a $16.30 to $17.475 range, according to Investing.com. The cancer cell-therapy name lagged the broader U.S. market. Lyell is still trading as a clinical-readout story, not on earnings. Its value depends on whether its main CAR T-cell drug, ronde-cel, can deliver enough on safety and efficacy to compete with approved therapies for large B-cell lymphoma.